CytomX Therapeutics CTMX Deferred revenue, net of current portion
Deferred revenue, net of current portion at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's deferred revenue, net of current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's deferred revenue, net of current portion?
- CytomX Therapeutics (CTMX) reported deferred revenue, net of current portion of $979K in Q1 2026.
- How has CytomX Therapeutics's deferred revenue, net of current portion changed year-over-year?
- CytomX Therapeutics's deferred revenue, net of current portion decreased by 94.0% year-over-year, from $16.21M to $979K.
- What is the long-term trend for CytomX Therapeutics's deferred revenue, net of current portion?
- Over 5 years (2020 to 2025), CytomX Therapeutics's deferred revenue, net of current portion has grown at a -64.4% compound annual growth rate (CAGR), from $276.65M to $1.59M.